The effect of oral probiotics on response to vaccination in older adults: a systematic review of randomised controlled trials

Abstract

This systematic review evaluated the impact of oral probiotics on the immune response to vaccination in older people. A literature search was performed in three electronic databases up to January 2023. Randomised controlled trials (RCTs) conducted in older people (age > 60 years) investigating oral probiotics and vaccine response outcomes were included. Characteristics and outcome data of the included studies were extracted and analysed and study quality was assessed using the Cochrane Risk of Bias Tool for randomised trials. Ten RCTs involving 1560 participants, reported in 9 papers, were included. Nine studies involved the seasonal influenza vaccine and one a COVID-19 vaccine. All studies used lactobacilli, some in combination with bifidobacteria. Studies reported outcomes including anti-vaccine antibody titres or concentrations, seroconversion and seroprotection. When comparing antibody titres, seroprotection rate and seroconversion rate between probiotic and placebo groups expressed as a response ratio, the weighted mean values were 1.29, 1.16, and 2.00 respectively. Meta-analysis showed that probiotics increase seroconversion rates to all three strains of the seasonal influenza vaccine: odds ratio (95% confidence interval) 2.74 (1.31, 5.70; p = 0.007) for the H1N1 strain, 1.90 (1.04, 3.44; p = 0.04) for the H2N2 strain, 1.72 (1.05, 2.80; p = 0.03) for the B strain. There was a low level of heterogeneity in these findings. Several studies were at high risk of bias due to missing outcome data. Lactobacilli may improve the vaccine response, but further research is needed to be more certain of this.

More information

Identifiers

ORCID for Caroline Childs: orcid.org/0000-0001-6832-224X

ORCID for Jonathan Swann: orcid.org/0000-0002-6485-4529

ORCID for Philip Calder: orcid.org/0000-0002-6038-710X

Catalogue record

Export record